Skip to main content
NIH funding notice RFA-MH-22-271

Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)

Closed on February 22, 2023.

Posted
September 19, 2022
Close date
February 22, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $209,375 in first-year total cost, median $209,375.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-S (06)]1

Most frequent institutions

  1. FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH1
Competing awards under RFA-MH-22-271 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Tau biomarkers in late-onset psychosis1R21MH135148-01KOPPEL, JEREMYFEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, NY$209,375ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-MH-22-271: Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional) | ScienceDex | ConductScience